Therapies for Rheumatoid Arthritis: Technologies and Global Markets

  • ID: 3789258
  • Report
  • Region: Global
  • 93 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 6
The Global Market for Therapies for Rheumatoid Arthritis is Expected to Reach Nearly $21.3 Billion by 2020 from $19.9 Billion in 2015, CAGR of 1.3%

FEATURED COMPANIES

  • AB Science
  • Baxalta Inc.
  • Celltrion Inc.
  • ELI Lilly
  • Kineta Inc.
  • Pfizer
  • MORE

The global market for therapies for rheumatoid arthritis reached $19.0 billion in 2014. The market is expected to reach nearly $21.3 billion by 2020 from $19.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 1.3% from 2015 to 2020.

Report Includes:

  • An overview of the global markets, therapies, and related technologies for treating Rheumatoid Arthritis (RA).
  • Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Discussion covering suppliers of therapeutic products for RA and analysis based on market share, product types, and geography (where data is available).
  • An overview of the disease including etiology, epidemiology, pathophysiology, risk factors and co-morbidities, and progression and outcomes.
  • An in-depth pipeline analysis, and biologic agents, both anti -TNF and non-TNF related currently under investigation or newly approved for use by the FDA are highlighted.
  • Relevant patent analysis.
  • Profiles of major players in the industry.

Report Scope:

The emphasis of this report is on the marketed products and also products in different stages of clinical development.

Special focus is placed on how new products and technologies will affect current market leaders in the RA treatment sector. Profiles are provided of companies projected to have products in the market during the forecast period and on companies with promising pipelines.

Profiles of the many emerging competitors in this sector provide a comprehensive assessment of the various products and technologies entering this market as well as marketing strategies being used to gain a competitive edge.

Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the rheumatoid arthritis market. The key players are J&J, AbbVie, Pfizer, GSK, Eli Lilly, Diachii Sankyo, Bristol-Myers Squibb (BMS), Roche, etc.

Intended Audience:

We have compiled detailed profiles of the RA therapeutic products on the market in the U.S. and around the world. All drugs in the Phase I, II and III stages of clinical development and pre-registration are discussed in this report. This study includes technical descriptions of these products, discussion of their individual efficacy and side effect profiles when possible, what stage of the disease they treat, the major companies focusing on their development and international aspects affecting these products. We provide sales forecasts and the reasoning behind our forecasts for products that are on the market already or that may enter the market through 2020.

This study will be of interest to members of the pharmaceutical, healthcare and biotechnology industries. It will also be a valuable resource for investors that invest in the pharmaceutical sector. It is written in such a way as to be accessible to an investor or businessperson while maintaining a high level of technical detail.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AB Science
  • Baxalta Inc.
  • Celltrion Inc.
  • ELI Lilly
  • Kineta Inc.
  • Pfizer
  • MORE

1: Introduction
- Study Goals And Objectives
- Reasons For Doing This Study
- Intended Audience
- Scope of Report
- Methodology
- Information Sources

2: Summary
- Table 0A: Global Market For Therapies For Rheumatoid Arthritis, By Therapeutic Class, Through 2020
- Figure 0A: Global Market For Therapies For Rheumatoid Arthritis By Therapeutic Class, 2014-2020
- Table 0B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, Through 2020
- Figure 0B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, 2014-2020

3: Disease Overview
- Etiology
- Pathophysiology
- Symptoms
- Prognosis
- Quality of Life
- Epidemiology

4: Disease Management
- Diagnosis
- Treatment Overview
- Biosimilars
- Competitive Assessment

5: Unmet Need And Opportunity
- Unmet Need
- Gap Analysis
- Opportunity

6: Pipeline Assessment
- Overview

7: Patent Assessments
- Table 33: List of Therapies For Ra In The Market, By Patent Expiry Date
- Table 34: List of Patents Issued For Ra Therapies
- Table 35: List of Patent Applications For Ra Therapies

8: Company Profiles
- Ab Science
- Abbott Laboratories
- Amgen Inc.
- Astellas
- Baxalta Inc.
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Celgene Corp.
- Celltrion Inc.
- Coherus Biosciences Inc.
- Daiichi Sankyo Co. Ltd.
- Eisai
- Eli Lilly
- Fujifilm Kyowa Kirin Biologics Co. Ltd.
- Glaxosmithkline
- Incyte Corp.
- Johnson & Johnson
- Kineta Inc.
- Mabtech Ab
- Mycenax Biotech Inc.
- Novartis Ag
- Ono Pharmaceutical Co. Ltd.
- Pfizer
- Roche
- Samsung Biologics Co. Ltd.
- Takeda Pharmaceuticals
- Ucb Group/Immunomedics

9: Drivers And Barriers
- Driver: Launch of Novel Drugs, Including Oral Jak Inhibitors And Novel Biologics For Ra
- Driver: Earlier Diagnosis And Treatment
- Driver: Market Entry of Biosimilars Will Bring A Therapy Option For Those Who Cannot Afford Branded Biologics
- Driver: Aging Population And Increasing Prevalent Cases of Ra
- Barrier: Efforts To Reduce Costs In The Treatment of Ra
- Barrier: Lack of Regulatory Guidelines For Biosimilars Will Delay Their Availability In Some Regions
- Barrier: Entry of Biosimilars Will Create A Less Expensive Treatment Alternative
- Table 36: Drivers And Barriers For Ra Therapies

List of Tables:
Summary Table A: Global Market For Therapies For Rheumatoid Arthritis, By Therapeutic Class, Through 2020
Summary Table B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, Through 2020
Table 1: Common Symptoms of Rheumatoid Arthritis
Table 2: Epidemiological Forecast For Diagnosed Prevalent Cases of Rheumatoid Arthritis, By Region, Through 2020
Table 3: Risk Factors And Comorbidities For Rheumatoid Arthritis
Table 4: The 1987 Acr Diagnostic Criteria For Ra
Table 5: The 2010 Acr/Eular Diagnostic Criteria For Ra
Table 6: Treatment Guidelines For Ra
Table 7: The Acr 2012 Criteria For Ra Remission, And Low, Moderate, And High Disease Activity
Table 8: The Acr/Eular 2011 Criteria For Ra Remission Used In The 2013 Update To The Eular Recommendations For Ra Management
Table 9: Recommendations For Patients With Symptomatic Early Ra
Table 10: Recommendations For Optimal Followup Laboratory Monitoring Intervals -
Table 11: Mostmost Prescribed Biologics For The Treatment of Ra (After Csdmards), By Region
Table 12: Minor Therapeutic Drug Classes Used To Treat Ra
Table 13: Ra Diagnosis Profile In The U.S.
Table 14: Ra Diagnosis Profile In France
Table 15: Ra Diagnosis Profile In Germany
Table 16: Ra Diagnosis Profile In Italy
Table 17: Ra Diagnosis Profile In Spain
Table 18: Ra Diagnosis Profile In The Uk
Table 19: Ra Diagnosis Profile In Japan
Table 20: Ra Diagnosis Profile In Australia
Table 21: Ra Diagnosis Profile In China
Table 22: Ra Diagnosis Profile In India
Table 23: Leading Drugs For Treatment of Ra
Table 24: Global Market For Major Biosimilars By Region And Type, Through 2020
Table 25: Global Market For Enbrel, By Region, Through 2020
Table 26: Global Market For Humira, By Region, Through 2020
Table 27: Global Market For Remicade (Infliximab), By Region, Through 2020
Table 28: Global Market For Actemra, By Region, Through 2020
Table 29: Global Market For Orencia (Abatacept), By Region, Through 2020
Table 30: Global Market For Rituxan (Mabthera), By Region, Through 2020
Table 31: List of Ra Therapies In Clinical Trials, By Phase
Table 32: List of Ra Therapies In Development, By Phase
Table 33: List of Therapies For Ra In The Market, By Patent Expiry Date
Table 34: List of Patents Issued For Ra Therapies
Table 35: List of Patent Applications For Ra Therapies
Table 36: Drivers And Barriers For Ra Therapies

List of Figures:
Summary Figure A: Global Market For Therapies For Rheumatoid Arthritis By Therapeutic Class, 2014-2020
Summary Figure B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, 2014-2020
Figure 1: Flowchart For The Management of Ra In Early Disease, According To The Acr2012 Recommendations
Figure 2: Flowchart For The Management of Ra In Established Disease, According To The Acr2012 Recommendations
Figure 3: Recommendations For Treatment of Early Ra
Figure 4: Flowchart For The Management of Patients With Ra, According To The 2013 Eular Recommendations

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AB Science
  • Baxalta Inc.
  • Celltrion Inc.
  • ELI Lilly
  • Kineta Inc.
  • Pfizer
  • MORE

Analyst Credentials:

Geeta Ogra Bedi has nearly two decades of global experience in the pharmaceutical/biotechnology and healthcare industries and is the Founder/Director of Providentia Research, a consulting firm that provides services in the area of auditing (PVG, GCP, GLP and GMP), medical writing and market research. She has worked with a variety of organizations internationally, ranging from contract research organizations and business partners to clinical sites, service providers and manufacturers. She led the quality assurance programs for the IND directed studies/clinical development/pharmacovigilance. She received an Appreciation Award from the President of India for exceptional contribution in the development of a new chemical entity (NCE), as well as an award for best poster at an international conference on Hypertension and Diabetes. She received her Bachelor's degree in Pharmacy and her Master's in Pharmacy/Pharmacology in New Delhi, India.

Note: Product cover images may vary from those shown
5 of 6
  • AB Science
  • Abbott Laboratories
  • Amgen Inc.
  • Astellas
  • Baxalta Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Celltrion Inc.
  • Coherus Biosciences Inc.
  • Daiichi Sankyo Co. Ltd.
  • ELI Lilly
  • Eisai
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.
  • Glaxosmithkline
  • Incyte Corp.
  • Johnson & Johnson
  • Kineta Inc.
  • Mabtech AB
  • Mycenax Biotech Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer
  • Roche
  • Samsung Biologics Co. Ltd.
  • Takeda Pharmaceuticals
  • UCB Group/Immunomedics
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll